Navigation Links
Bone-Strengthening Drug Guards Against Spread of Breast Cancer
Date:4/1/2010

Zoledronic acid protected against chemotherapy-related bone loss, metastasis, study finds

WEDNESDAY, March 31 (HealthDay News) -- The bone-strengthening drug zoledronic acid (Zometa) reduces the spread of breast cancer by preventing chemotherapy-related bone loss, a new study suggests.

Tumor cells released from the primary breast cancer site often travel to the bone marrow and spread from there to other areas of the body. Chemotherapy speeds up bone turnover, which releases bone-derived growth factors that can promote tumor growth in breast cancer patients.

It's been suggested that zoledronic acid -- which reduces bone loss by slowing the activity of cells that destroy bone -- can make bone marrow a less inviting place for cancer cells.

The new phase 2 trial included 120 women undergoing chemotherapy for locally advanced breast cancer. Some of the patients received 4 milligrams of zoledronic acid every three weeks for one year starting with their first dose of chemotherapy, while others received no zoledronic acid.

Bone marrow samples were taken at the start of the study and again after three months and one year of treatment. At the start of the study, 45.7 percent of patients had detectable tumor cells in their bone marrow. After three months of treatment, women who received zoledronic acid and chemotherapy had fewer detectable tumor cells than those who received chemotherapy alone, according to Rebecca Aft, of the Washington University School of Medicine in St. Louis, and colleagues.

Among women who had no tumor cells in their bone marrow at the start of the study, 87 percent of those in the zoledronic acid group were free of tumor cells at three months, compared with 60 percent of those who received chemotherapy alone. One year after treatment, the rates were 40 percent and 33 percent, respectively, the study authors noted.

The researchers also found that zoledronic acid prevented chemotherapy-related bone loss. Among patients who had low bone mineral density at the start of the study, 44 percent of those who took zoledronic acid had normal bone density after one year and significant decreases in bone-turnover markers at three months and one year.

The study, which appears online March 31 in The Lancet Oncology, was funded by Novartis Pharmaceuticals and Pfizer Inc.

More information

The U.S. National Cancer Institute has more about breast cancer treatments.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, March 31, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. OldHouseWeb.com Educates Homeowners on Lead Poisoning Safeguards During National Poison Prevention Week
2. Vitamin D Plus Calcium Guards Against Fractures
3. Exercise Guards White Blood Cells Against Aging
4. Research confirms that some forms of massage help against low-back pain
5. Study finds surgical masks provided effective protection of health-care workers against H1N1
6. IPhone App is New Tool in the Fight Against Breast Cancer
7. Food Safety Attorney Fred Pritzker Calls for Criminal Sanctions Against Food Poisoners
8. Motherhood a Buffer Against Suicide
9. State Legislators Last Line of Defense Against ObamaCare
10. Poorly understood cell plays role in immunity against the flu
11. Study Details Machinery of Immune Protection Against Inflammatory Diseases Like Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... ... January 15, 2017 , ... Going above and beyond ... strives to better communities around the world by offering the Gensuite team and ... opportunity for team members to become involved in a cause that is bigger ...
(Date:1/15/2017)... Rosa, CA (PRWEB) , ... January 15, 2017 ... ... nominate their choice of best physicians in eight Bay Area counties for 2017. ... by the healthcare research company managing the award process. Results were announced the ...
(Date:1/14/2017)... Minneapolis, MN (PRWEB) , ... January 14, 2017 ... ... to present the distinctions among their expanding line of activated charcoal products. With ... emphasizes the importance of categorizing their products according to how they cater to ...
(Date:1/13/2017)... ... 2017 , ... People with type 2 diabetes know to ... as checking the nutrition label on foods for grams of sugar. But carbohydrates ... proteins can influence — either positively or negatively — insulin secretion and glucose ...
(Date:1/13/2017)... ... January 13, 2017 , ... With the increasing public ... of providing additional organic alternatives for customers who have grown more conscious about ... line of all-natural activated charcoal products, Moody Zook Chief Executive Officer Nate Ginsburg ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... SAN FRANCISCO, Calif. , Jan. 16, 2017 /PRNewswire/ ... that on January 3, 2017 and January 16, 2017 ... the grant of inducement stock options to purchase an ... new employees. These awards were granted pursuant to the ... inducement material to the new employees entering into employment ...
(Date:1/16/2017)... Colo. , Jan. 16, 2017 CBDRx, ... donate large amounts of phyto-nutrient rich hemp extract to ... the donation of their proprietary hemp extract to Veteran,s ... CBDRx the best hemp company in the world and ... best, most nutritious, full spectrum phyto-nutrient rich hemp extract ...
(Date:1/15/2017)... -- Le conseil d,administration de SurgaColl Technologies Ltd., ... la régénération de tissus humains, annonce la nomination de ... effet immédiat. ... Bill est un dirigeant expérimenté à l,international dans l,industrie ... générale et de direction au sein de sociétés internationales spécialisées ...
Breaking Medicine Technology: